Pharmaceuticals

Increasing leukemia prevalence is driving the Elitek or Fasturtec Market 2026

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Elitek Or Fasturtec Market Expected To Change Between 2026 And 2030?

The historical growth can be attributed to a rise in chemotherapy applications, the established rates of complications from tumor lysis syndrome, the initial endorsements of rasburicase, the broadening of oncology services in hospitals, and the increasing occurrence of cancer.

The projected increase over the forecast timeframe is driven by an increasing worldwide prevalence of cancer, the broadening of initiatives for childhood cancer treatment, enhanced early assessment of tumor lysis syndrome risk, the proliferation of specialized cancer treatment facilities, and breakthroughs in supportive care for cancer patients.

Key developments expected during the forecast period encompass a heightened emphasis on supportive care for cancer, greater application in managing tumor lysis syndrome, an expansion of infusion therapies administered in hospitals, the wider availability of treatments for childhood cancer, and refined safety procedures for chemotherapy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20049&type=smp

What Underlying Factors Are Accelerating The Growth Of The Elitek Or Fasturtec Market?

The increasing incidence of leukemia is anticipated to fuel the expansion of the elitek or fasturtec market in the future. Leukemia, characterized by the uncontrolled multiplication of abnormal white blood cells in the bone marrow, often results from genetic mutations, environmental factors, or exposure to radiation and specific chemicals. The surge in leukemia cases can be attributed to factors such as an aging demographic, genetic predispositions, environmental exposures, and enhancements in diagnostic capabilities. Elitek (Fasturtec) aids leukemia patients by lowering elevated uric acid levels that arise from tumor lysis syndrome (TLS), a condition where cancer therapies rapidly destroy leukemia cells, releasing substantial amounts of uric acid into the bloodstream. As an illustration, in 2024, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported that leukemia cases climbed to 62,770, marking an increase from the 59,610 recorded in 2023. Consequently, the growing prevalence of leukemia is propelling the elitek or fasturtec market.

How Is The Elitek Or Fasturtec Market Structured Across Different Segments?

The elitek or fasturtec market covered in this report is segmented –

1) By Dosage Form: Injectable, Lyophilized Powder

2) By Indication: Tumor Lysis Syndrome (TLS), Other Indications

3) By Patient Type: Pediatric Patients, Adult Patients

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Trends Are Shaping The Future Of The Elitek Or Fasturtec Market?

A significant trend within the elitek or fasturtec market involves an increasing focus on adult applications, particularly for managing tumor lysis syndrome (TLS) in cancer patients. Given the rising incidence of TLS among individuals undergoing chemotherapy for aggressive malignancies like leukemia, lymphoma, and solid tumors, there is a heightened demand for effective treatments for this critical condition. Companies operating in this segment are working to broaden their product’s utility beyond pediatric indications, targeting a wider array of cancer therapies. For example, in October 2023, Sanofi S.A., a France-based pharmaceutical company, secured FDA approval for Elitek. This approval is for the initial management of plasma uric acid levels in adult patients with leukemia, lymphoma, and solid tumors receiving anti-cancer therapy that might lead to tumor lysis syndrome (TLS) and elevated uric acid levels. This endorsement is substantiated by pivotal Phase 3 trial outcomes, which demonstrated that Elitek notably reduced plasma uric acid levels compared to the standard oral allopurinol care in adults at risk for TLS, offering an essential treatment option for this potentially fatal condition.

Which Major Players Dominate The Elitek Or Fasturtec Market?

Major companies operating in the elitek or fasturtec market are Sanofi S.A.

Read the full elitek or fasturtec market report here:

https://www.thebusinessresearchcompany.com/report/elitek-or-fasturtec-global-market-report

Which Region Is Projected To Dominate The Elitek Or Fasturtec Market During The Forecast Period?

North America was the largest region in the elitek or fasturtec market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elitek or fasturtec market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Elitek Or Fasturtec Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20049&type=smp

Browse Through More Reports Similar to the Global Elitek Or Fasturtec Market 2026, By The Business Research Company

Financial Advisory Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-advisory-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Hedge Fund Market Report 2026

https://www.thebusinessresearchcompany.com/report/hedge-fund-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795